0.000
0.00 (0.00%)
AISkor Stockmoo
| Nilai | NA |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Pulangan atas Modal info | NA |
| Kesihatan Kewangan info | NA |
| Trend Perolehan info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa | NA |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Kekuatan Aliran info | NA |
| Persediaan Teknikal info | NA |
| Corak Lilin info | NA |
| Aliran Jangka Sederhana info | NA |
| Sentimen 100% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Pegangan info | NA |
| Sentimen Berita info | NA |
| Wang Pintar | NA |
| Aktiviti Orang Dalam info | NA |
| Aliran Institusi info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tiada tonggak mempunyai bacaan yang jelas, jadi skor tidak berubah. | |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | NA |
| Tiada aliran jelas bagi jangka pendek, sederhana dan panjang. info | |
| Tiada isyarat jelas daripada sokongan dan rintangan. info | |
| Skor Akhir | 0.00 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Timber Pharmaceuticals, Inc. | - | - |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| TMBR | - | - | - | - | 0.0 |
| CYBN | 359 M | - | - | - | 0.0 |
| LCTX | 195 M | - | - | 2.91 | -2.3 |
| NRXS | 60 M | - | - | 18.58 | -1.2 |
| CVM | 21 M | - | - | 2.22 | -3.7 |
| NHWK | 20 M | - | - | 0.260 | 0.0 |
|
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |